|Bid||242.47 x 1000|
|Ask||0.00 x 1200|
|Day's Range||241.32 - 247.75|
|52 Week Range||225.65 - 355.88|
|Beta (3Y Monthly)||1.11|
|PE Ratio (TTM)||19.95|
|Earnings Date||May 1, 2019|
|Forward Dividend & Yield||2.00 (0.75%)|
|1y Target Est||359.75|
Healthcare stocks are taking a hit this week. Proposed legislation that would tighten control over pharmacy benefit managers-- or PBMs-- are weighing down shares. Who are PBMs and what impact do they have on what we pay for our prescription drugs? Robin Feldman, author of Drugs, Money and Secret Handshakes, the Unstoppable Growth of Prescription Drug Prices, talks with Yahoo Finance's Julie Hyman and Adam Shapiro.
LOUISVILLE, Ky.-- -- Five of Humana’s seven original Bold Goal communities reduced Unhealthy Days Humana Medicare members in San Antonio achieved a 9.8 percent improvement Screened 500,000 people for social determinants of health across Bold Goal communities and Humana, setting a new goal of 1 million by the end of 2019 Humana Inc. today unveiled the “2019 Bold Goal Progress Report,” which details ...
Shares of UnitedHealth, Cigna, Anthem, and others have weakened on fear of Medicare for All. But the odds are that this political fever will abate.
Humana Inc. announced today that its Board of Directors has declared a cash dividend to stockholders of $0.55 per share payable on July 26, 2019 to stockholders of record as of the close of business on June 28, 2019.
Anthem's (ANTM) first-quarter earnings are likely to benefit from an impressive operating performance and robust revenues, driven by its strong businesses.
While the broad market zooms ahead, health care stocks are being weighed down by regulatory threats even as earnings forecasts remain strong.
Humana (HUM) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Investing.com - UnitedHealth fell Tuesday, giving up early post-earnings gains as political concerns overshadowed solid results.
CEO Julia Taylor Cheek founded EverlyWell in 2015. Her company enables people to order tests, such as fertility and food-sensitivity diagnostics, and obtain doctor-reviewed results and feedback within days.
According to GuruFocus' list of 52-week lows, these guru stocks have reached their 52-week lows. The price of UnitedHealth Group Inc. (UNH) shares has declined to close to the 52-week low of $223.22, which is 23.3% off the 52-week high of $287.94. The company has a market cap of $214.19 billion.
April started poorly for Walgreens Boots Alliance (NASDAQ: WBA). A weak second-quarter earnings report sent Walgreens stock down 12.8% on April 2. With a downtrend very clearly in place, why should investors even consider WBA stock after the plunge?Source: Mike Mozart via FlickrWalgreens reported non-GAAP earnings of $1.64 as revenue grew 4.6% to $34.53 billion. A confluence of negative headwinds hit the company's bottom line. Higher reimbursement pressures, lower generic deflation, lower brand inflation and weak performance from restructuring programs led to the poor results. * 7 Marijuana Companies: Which Pot Stocks Should You Buy? Markets now know why Walgreens, along with CVS (NYSE: CVS) and Rite Aid (NYSE: RAD) fell ahead of the results report. Markets even sold off health care plan stocks like Cigna (NYSE: CI) and Humana (NYSE: HUM) in 2019: there are significant market-wide headwinds.InvestorPlace - Stock Market News, Stock Advice & Trading Tips Long-Term Growth and Walgreens StockWalgreens has four strategic priorities aimed at delivering sustainable, long-term growth. It is accelerating the company's digital footprint, transforming its approach to retail, creating neighborhood health destinations, and implementing a revamped cost management program.This jargon on cost reduction will not mean much to the shareholder who just lost 12.8%.To stabilize the business as reimbursement pressures worsen, Walgreens must improve same-store sales. The near-term problems in achieving growth here are the acquired Rite Aid stores. Sales grew 7.3% and organic sales grew 1.6% but adjusted growth profit declined a substantial 3.5% in the quarter. Pharmacy and retail both fell. Gross margin from Pharmacy fell 260 basis points.A 6.8% drop in SG&A spend, along with cost savings initiatives ahead may slow the weakening operating income, which fell 11.9% in the second quarter. Opportunity and Walgreens StockA weaker cough, cold, and flu season added to Walgreens' woes but could create an opportunity for value investors. Since results were so weak, Walgreens could move up from here if management moves swiftly to balance its operating expenses against the higher reimbursement pressure.Digitization will help Walgreens increase its efficiency but it needs more than that. Still, bringing in the Microsoft (NASDAQ: MSFT) Teams to consolidate its internal digital team under a Chief Digital Officer will improve back-office efficiency.Walgreens restructured management such that there are two teams in development and delivery. One accomplishment is that its 5-star rated app has 55 million downloads. Another is it has 85 million active Balance Rewards members. The drug store clearly has the potential to reach out to its customer base through the mobile app. What is not clear yet is how much more business the app will bring for Walgreens. Near-term OutlookThe weak current third quarter for Walgreens will follow with improvements in Q4. While investors are disturbed by management's realistic goal-setting of mid-to-high single-digit growth, the reset in expectations creates an entry point for value investors.Plus, with the company working to offset the generic impact by 50% - 60%, profit margins may start to stabilize. Overall, it plans to cut costs by $1.5 billion. That is a substantial number and will benefit the company's long-term health.Walgreens will also shift its resources towards growing its Health & Beauty segment where it is confident that it can win an already very attractive business. The Bottom Line on Walgreens StockThe analyst positional changes are mixed. According to Tipranks, one analyst called WBA stock a "sell" while six have a "hold" and two analysts have a "buy." The average price target is $61 a share, which suggests the stock has an upside of 11%.Patient investors may want to wait for the selling-pressure to ease for a few days. Walgreens is already trading at a discount but this could widen. Still, even though drug store stocks are out of favor, Walgreens is the strongest of the available picks.Disclosure: As of this writing, the author did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Internet Stocks to Watch * 7 AI Stocks to Watch with Strong Long-Term Narratives * 10 Dow Jones Stocks Holding the Blue Chip Index Back Compare Brokers The post There's a Buy the Dip Opportunity in Walgreens Stock but It Isn't Now appeared first on InvestorPlace.
Healthcare sector-specific ETFs took a blow Friday after the U.S. Congress threatened legislative action on rising costs of prescription drugs and the Trump administration challenged former President Barack ...
The Zacks Analyst Blog Highlights: McDonald's, Enterprise Products Partners, Charles Schwab, BB&T and Humana
Asian stock markets were mostly higher Friday after a mixed Wall Street close on listless trading. Benchmarks in Tokyo, Sydney and Seoul rose. China's main index was up 1 point while Hong Kong retreated. ...
The 26th annual West Virginia Senior Sports Classic (WVSSC), the multi-sport competition for seniors, will be held Thursday, May 2 through Saturday, May 4, 2019, primarily in the Charleston area. For the first time, leading health and well-being company Humana Inc. (HUM) will be the games’ presenting sponsor. Several hundred athletes from West Virginia and beyond are expected to participate, ranging in age from 50 to 90+.
Five of the nation's largest pharmacy benefit managers deny that the so-called backdoor deals with drug manufacturers are responsible for the sticker shock some patients see. In written testimony submitted to the Senate Finance Committee, they blasted the drug industry for the rising cost of brand-name drugs. Executives from the nation's largest pharmacy benefit managers denied on Tuesday that the industry's so-called backdoor deals with drugmakers are responsible for the increasingly higher prices patients pay for medication, pointing the finger at Big Pharma instead.
Executives from the nation's largest pharmacy benefit managers denied that so-called "backdoor deals" with drug manufacturers are responsible for the high prices patients pay for drugs.
Humana Inc. (HUM) will release its financial results for the first quarter 2019 (1Q19) on Wednesday, May 1, 2019 at 6:30 a.m. eastern time. The company will host a conference call at 9:00 a.m. eastern time that morning to discuss its financial results for the quarter and earnings guidance for 2019. A webcast of the 1Q19 earnings call may also be accessed via Humana’s Investor Relations page at www.humana.com.
Certain health conditions— including diabetes, high blood pressure and stroke— are not only more common among African Americans than other populations, but they are also more fatal, according to data from the U.S. Centers for Disease Control and Prevention (CDC). In an effort to combat this health disparity on a local level, a new health initiative by the Black Health Care Coalition of Kansas City in partnership with leading health and well-being company Humana Inc.
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! When you buy a stock there is always a possibility that it could drop 100%. But on the bright side, you can make fa...